CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PREVENT project aims to develop a combination therapy using nanomedicine for treating castration-resistant prostate cancer, alongside a diagnostic test based on extracellular vesicles. This approach seeks to enhance drug delivery and improve monitoring of treatment efficacy.
Prostate cancer (PC) is one of the deadliest types of cancer in males worldwide.
Early stage PC is often curable but many patients develop castration-resistant prostate cancer (CRPC), resulting in lethal end-stage disease.
Prostate specific antigen (PSA) plasma levels have been traditionally exploited for diagnosis and prognosis.
However, the application of PSA as a biomarker is associated with predictability issues.
Advanced therapies are required for the treatment of CRPC, guided by a reliable…
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Canada, Vancouver
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
